Interstitial lung diseases in inborn errors of immunity

Curr Opin Allergy Clin Immunol. 2023 Dec 1;23(6):500-506. doi: 10.1097/ACI.0000000000000951. Epub 2023 Oct 12.

Abstract

Purpose of review: Our goal is to review current understanding of interstitial lung disease (ILD) affecting patients with inborn errors of immunity (IEI). This includes understanding how IEI might predispose to and promote development or progression of ILD as well as how our growing understanding of IEI can help shape treatment of ILD in these patients. Additionally, by examining current knowledge of ILD in IEI, we hope to identify key knowledge gaps that can become focus of future investigative efforts.

Recent findings: Recent identification of novel IEI associated with ILD and the latest reports examining treatment of ILD in IEI are included. Of noted interest, are recent clinical studies of immunomodulatory therapy for ILD in common variable immunodeficiency.

Summary: ILD is a frequent complication found in many IEI. This article provides a guide to identifying manifestations of ILD in IEI. We review a broad spectrum of IEI that develop ILD, including antibody deficiency and immune dysregulation disorders that promote autoimmunity and autoinflammation. This work integrates clinical information with molecular mechanisms of disease and diagnostic assessments to provide an expedient overview of a clinically relevant and expanding topic.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Autoimmunity
  • Common Variable Immunodeficiency*
  • Humans
  • Immunomodulation
  • Lung Diseases, Interstitial* / diagnosis
  • Primary Immunodeficiency Diseases*